COMPANY PROFILE
“In 2008 we launched Translational Pharmaceutics™, an innovative platform that integrates drug substance, drug product manufacturing and clinical testing activities, saving customers more than 12 months of time in their drug development plans. We have demonstrated the timeline acceleration translates into multi-million dollar financial benefits for customers and also gives them a far greater chance of success in getting new medicines to patients, faster.” Mark Egerton, CEO, Quotient Sciences
Summary
Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway for small molecules & peptide drug programs. We cut through silos across a range of drug development capabilities, saving precious time and money in getting drugs to patients.
We work with customers in a flexible way by either designing and delivering fully integrated programs at each stage of the development lifecycle, or by providing them support through tailored individual services including Drug Substance Synthesis & Manufacturing, Formulation Development, Clinical Trial Manufacturing, Commercial Manufacturing, Clinical Pharmacology, Data Sciences, Bioanalysis and Drug Development Consulting.
Quotient Sciences has over 30 years of experience developing a breadth of formulations across a range of indications and across an array of drug product formats including oral, inhaled, parenteral & topical. We also have a depth of expertise in modified release, oral peptides, ADME studies, Radiolabelling, Scintigraphy, Pediatrics and possess the ability to handle highly potent compounds. Our innovative approach to formulation development is based on our proven track record in early clinical evaluation delivering phase-appropriate formulations across the product development pathway from candidate selection through to commercial product launch.
Key Leadership
Mark Egerton, Chief Executive Officer
Mark joined Quotient as CEO in 2005 and has over 25 years’ experience in the pharmaceutical and biotech industry. He has worked in a range of organizations including large multinational pharmaceutical companies through to private venture funded biotechnology companies.
Following his PhD (Biochemistry, University of Edinburgh) and post-doctoral research (Biochemistry, Biozentrum, Basel), Mark began his pharmaceutical R&D career at Novartis (then Sandoz) in Switzerland and then AstraZeneca in the U.K. During this time he was responsible for discovery projects across a number of therapeutic areas. Mark then joined Incyte Pharmaceuticals, a Californian biotechnology company, where he was responsible for a business unit focused on the application of genomic technologies to pre-clinical development. He returned to the UK with Incyte Pharmaceuticals to head up European Business Operations and was responsible for leading that organization to record levels of performance. Prior to joining Quotient, Mark was the Chief Business Officer at Oxagen, a UK biotech company focused on novel therapeutics for Respiratory diseases.
Peter Scholes, PhD, Chief Scientific Officer
Dr Peter Scholes is the Chief Scientific Officer at Quotient Sciences. Peter has over 25 years’ experience in the pharmaceutical industry. In his role at Quotient he has been instrumental in identifying and implementing the innovative and flexible benefits of integrating pharmaceutical development and clinical testing in early research. He is responsible for Quotient’s scientific strategy, identifying new technologies, capabilities and services to accelerate the development of medicines for patients.
